Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
about
Clinical management of localized colon cancer with capecitabinePharmacologic resistance in colorectal cancer: a reviewIncidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trialsPharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsIncrease of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancerS-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis.PUMA mediates the combinational therapy of 5-FU and NVP-BEZ235 in colon cancerIdentification of novel germline polymorphisms governing capecitabine sensitivity.Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer.A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancerCapecitabine in the treatment of esophageal and gastric cancers.X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.Real-world resource use and costs of adjuvant treatment for stage III colon cancer.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.Melatonin synergizes the chemotherapeutic effect of 5-fluorouracil in colon cancer by suppressing PI3K/AKT and NF-κB/iNOS signaling pathways.Expression of IARS2 gene in colon cancer and effect of its knockdown on biological behavior of RKO cells.MicroRNA-494 sensitizes colon cancer cells to fluorouracil through regulation of DPYD.Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.Latest developments and emerging treatment options in the management of stomach cancer.An active molecule from Pulsatilla chinensis, Pulsatilla saponin A, induces apoptosis and inhibits tumor growth of human colon cancer cells without or with 5-FU.Time trends in chemotherapy (administration and costs) and relative survival in stage III colon cancer patients - a large population-based study from 1990 to 2008.Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma.Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.Overexpression of GRK6 associates with the progression and prognosis of colorectal carcinoma.Preliminary results of trial NPC-0501 evaluating the therapeutic gain by changing from concurrent-adjuvant to induction-concurrent chemoradiotherapy, changing from fluorouracil to capecitabine, and changing from conventional to accelerated radiother
P2860
Q24611758-00D87C64-7E78-46AF-A3DA-80B9D3910BF3Q26769850-AD3EC445-C114-4B31-85C9-A53029484720Q27028095-23E2D1D8-C2DB-4E51-B5AC-FDEF2ACEBDF6Q34008793-9A1C34AE-D541-495C-A4B4-5F77DF7EC928Q34561552-BB5A76E9-408B-47F1-83A4-D8EE15DDC7EEQ35070531-1183BD1E-2EF1-4DEE-89C2-D96EA9BBCB61Q35080136-67D9787C-EE25-4838-AA0C-87F900FFB4D5Q35987363-3DB35B1C-539F-4700-A27D-056D0455D2BDQ36147462-3BE78D06-6F88-47A3-8332-C03FDD611C64Q36897944-84020271-967C-4994-8AEC-DED2F112BD98Q37131721-7897D147-1B76-465B-B2C6-DBAE356E2E3FQ38148794-3EB85CDE-0197-41A9-8B10-4744BBC8EC50Q38162285-44D76853-8A34-4B49-9AD1-3413898F85DEQ38174218-A4B8971B-AB0C-40B6-A841-D762F508E816Q38204673-19C7FDBF-703B-4C0A-9E4C-0077B5FC807BQ38730168-CC819250-8DE9-4A4D-A574-C28C5C80DBD6Q38807237-F894FC28-933D-42F7-B28A-E8E45CAD6917Q38887255-4ED63C18-97F5-4DB5-84C2-849BFB2554FAQ39470148-21D0A230-E03D-44EF-8D6A-9F9B2B4AC71FQ41898734-3D3AD646-001B-4492-924D-186587928E3EQ42266764-8081D68E-8C36-421A-94A4-3C2437427B0EQ45710823-8E194F9F-75B7-450D-AF4E-1B784C44D30AQ46319469-5BB3F8C5-6C76-4EAD-B49A-DF990E22401BQ47291560-FEA6E8BA-374F-4180-976B-9DCD37CDB4CFQ50041173-50DAA6A8-A84C-46EE-B0E5-0EE395C97B6EQ51058654-1925E34F-43BF-449D-BAA6-10C5560D5D29Q52649654-95F1085E-3716-48A5-B5C1-83BB42D62177Q53662723-0D29EC7A-230F-46E2-9119-E50DC4FBCBB6
P2860
Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@ast
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en-gb
type
label
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@ast
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en-gb
prefLabel
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@ast
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en-gb
P2093
P2860
P50
P356
P1433
P1476
Efficacy of capecitabine versu ...... idual data from 6171 patients.
@en
P2093
E Van Cutsem
P2860
P304
P356
10.1093/ANNONC/MDR031
P577
2011-03-17T00:00:00Z